More annual reports from Nanollose Limited:
2023 ReportPeers and competitors of Nanollose Limited:
Entera Bio Ltd.NANOLLOSE LIMITED 
ABN 13 601 676 377 
ANNUAL REPORT - 30 JUNE 2023 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
CORPORATE DIRECTORY 
CHAIRMANS’ LETTER TO SHAREHOLDERS 
DIRECTORS’ REPORT 
AUDITOR’S INDEPENDENCE DECLARATION 
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
STATEMENT OF FINANCIAL POSITION 
STATEMENT OF CHANGES IN EQUITY  
STATEMENT OF CASH FLOWS  
NOTES TO THE FINANCIAL STATEMENTS 
DIRECTORS’ DECLARATION 
INDEPENDENT AUDITOR’S REPORT 
ASX ADDITIONAL INFORMATION 
PAGE 
3 
4 
5 
22 
23 
24 
25 
27 
28 
49 
50 
53 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
 PAGE  2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CORPORATE DIRECTORY 
DIRECTORS 
JOINT COMPANY SECRETARIES 
REGISTERED AND PRINCIPAL OFFICE 
AUDITORS 
SHARE REGISTRY 
HOME EXCHANGE 
SOLICITORS 
Wayne Best 
Winton Willesee 
Terence Walsh  
Heidi Beatty 
Erlyn Dawson  
Emily Spano 
Suite 5 CPC, 145 Stirling Highway 
NEDLANDS WA 6009 
Telephone: (08) 9389 3120 
Website: www.nanollose.com 
Email: info@nanollose.com 
RSM Australia Partners 
Level 32 Exchange Tower, 2 The Esplanade 
Perth WA  6000 
Automic Registry Services 
Level 5, 191 St Georges Terrace 
PERTH WA  6000 
Telephone: (08) 9324 2099 
Australian Securities Exchange  
Level 40, Central Park 
152-158 St George’s Terrace 
PERTH WA 6000 
ASX Code: NC6, Options NC6OA 
Fairweather Corporate Lawyers 
Suite 2, 589 Stirling Highway 
Cottesloe WA 6011 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
 PAGE  3  
 
 
 
 
 
 
 
CHAIRMAN’S LETTER TO SHAREHOLDERS  NANOLLOSE LIMITED ANNUAL REPORT 2023  PAGE  4 Dear fellow shareholders,   It is my pleasure to present to you the 2023 Annual Report for Nanollose Limited (ASX:NC6) (‘Nanollose’ or ‘the Company’), with accompanying financial statements for the year ended June 30, 2023.   The Company’s achievements over the past 12 months reflect the strong execution in pursuit of its stated business strategy – to commercialise proprietary technology at the forefront of important changes taking place in the global fashion and textiles industry.   Operations were highlighted by the ongoing advancement of our flagship Nullarbor™ fibre technology where Nanollose extended its R&D partnership with one of the world’s largest rayon producers and added new collaborations with several leading textile manufacturers. That work was accompanied by key breakthroughs across the group’s product development suite, including its Jelli Grow™ technology and ‘vegan leather’ products.  For Nanollose, these developments give our shareholders plenty to look forward to over the next financial year and beyond. The Board and management team remain fully committed to the strategy of converting our unique R&D pipeline into commercialisation opportunities, in line with the structural reallocation of capital towards green manufacturing solutions for the garment industry globally.    Near-term, Nanollose is on track to present results for the third pilot production spin of our Nullarbor fibres with Birla Cellulose, a division of multinational Indian conglomerate Aditya Birla Group. The first two pilot runs have already demonstrated the ability of our technology to produce Nullarbor-20 and Nullarbor-30 Forest-Friendly fibres at scale and we envisage the percentage of microbial cellulose will increase further in subsequent pilot spins.   These breakthroughs leave the Company well-positioned to demonstrate the application of the technology at commercial scale, and we are continuing to build momentum with Birla and our network of global manufacturing partners to finalise product-market-fit.   Furthermore, the commercial opportunity for our Nullarbor fibre is complemented by equally exciting developments across our product pipeline. Of note during the period, Nanollose achieved a major R&D breakthrough for its Jelli Grow technology by creating a novel methodology for drying microbial cellulose.   The ability to dry microbial cellulose, without destroying its water holding capacity, was a key R&D objective of the Company required for the commercialisation of Jelli Grow and similar materials. In that context we are particularly pleased by the results and have filed a new patent application with IP Australia to maximise the potential market opportunity realised through our ongoing R&D efforts.  Those breakthroughs for the Company’s Nullarbor fibres and its Jelli Grow formulation are just two of several initiatives during the 2023 financial year that position Nanollose as one of the most unique technology companies on the ASX.   As momentum continues to build, our strategy remains focused on converting our technology into a viable source of scalable, sustainable fabric supply for the global fashion and textiles industry, at a time when demand for such solutions is expected to increase in the years ahead.  We’re excited to partner with our global development team in pursuit of that goal. In presenting our 2023 Annual Report, I’d sincerely like to thank our shareholders for their ongoing support of the work we are doing in this field. On behalf of the Board and management team, the Company looks forward to commercialising our technology and unlocking value for our investors in the months and years ahead.    Dr Wayne Best Executive Chairman DIRECTORS’ REPORT 
The directors present their report, together with the financial statements of Nanollose Limited (referred to hereafter as 
the 'Company') for the year ended 30 June 2023. 
BOARD OF DIRECTORS 
The names and details of the Directors in office during the financial period and until the date of this report are set out 
below. Each Director was in office for the whole of the financial period, unless otherwise stated.  
•  Wayne Best 
Executive Chairman  
•  Winton Willesee 
Non-Executive Director 
• 
Terence Walsh 
Non-Executive Director 
•  Heidi Beatty 
Non-Executive Director  
PRINCIPAL ACTIVITIES 
Nanollose Limited is a leading biomaterials company, commercialising scalable technology to create fibres, fabrics, and 
other materials with minimal environmental impact. During the financial year, the principal continuing activities of the 
Company consisted of research and development, and promotion of the Company’s microbial cellulose  technologies. 
The  primary  focus  has  been  directed  towards  the  development,  scale  up  and  ultimate  commercialisation  of  the 
Company’s Tree-Free rayon fibre for use in textiles (NullarborTM) and non-woven applications (Nufolium™). 
DIVIDENDS PAID OR RECOMMENDED 
There were no dividends declared or paid during the financial year (2022: Nil). 
OPERATING RESULTS 
During the year, the principal continuing activities of the Company consisted of research and development, and 
promotion of the Company’s microbial cellulose technologies. The loss for the Company after providing for income tax 
amounted to $1,345,656 (30 June 2022: $1,566,504). 
REVIEW OF OPERATIONS 
Nanollose Limited (ASX:NC6) is a leading biomaterials company commercialising scalable technology to create forest 
friendly fibres, fabrics and other materials with minimal environmental impact.  
Nanollose uses a natural fermentation process to grow microbial cellulose from which it produces Tree-Free and Forest-
Friendly rayon fibres, which are primed to become an alternative to conventional tree-based rayon fibres. The Company 
holds a number of proprietary technologies to convert waste and by-products from the agricultural and food industries 
into unique eco-friendly tree-free rayon fibres for textiles, non-woven fabrics and other industrial applications.  
During the 2023 financial year, the Company made another round of important R&D breakthroughs as it  advances its 
technologies through its product pipeline from development to commercialisation. Details of the group’s operational 
highlights in FY23, including its Nullarbor™ fibres, Jelli Grow™ formulation, and new ‘vegan leather’ materials, are set 
out below: 
Second pilot production run of Nullarbor™ fibres 
In April 2023, Nanollose successfully completed the second pilot production of its ‘Forest-Friendly’ Nullarbor™ cellulose 
fibres, with R&D partner Birla Cellulose. 
The second pilot run successfully achieved its target objective to increase the microbial cellulose content, producing the 
first batch of Nullarbor-30™. Approximately 150kg of Nullarbor-30 was produced, consisting of 30% microbial cellulose 
and 70% FSC certified wood pulp, in addition to another 90kg of Nullarbor-20™. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
                   PAGE  5 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
As with its first pilot spin, the Company has now commenced the conversion of fibre from the second spin into fabrics 
with its partner Paradise Textiles for distribution to selected partners for sampling and incorporation into garments. 
Nullarbor™ product development with global production partners 
Earlier  in  the  2023  financial  year,  Nanollose  delivered  Nullarbor-20  fibre  from  the  first  pilot  spin  to  its  global 
manufacturing partners including Orta and Paradise Textiles.  
The Nullarbor-20 was spun into yarns and then converted into a variety of different fabrics. The fibre and yarns received 
universally positive feedback from the partners for their behaviour and processability in the industrial spinning, weaving 
and knitting machines. 
Paradise Textiles converted 135kg of Nullarbor-20 fibre into several types of yarn and subsequently knitted those yarns 
into a variety of fabrics – highlighting the versatility of Nanollose’s solution. Paradise also undertook extensive industrial 
testing of the fabrics which confirmed their high quality. 
Paradise  is  the  material  science  and  innovation  hub  of  the  Alpine  Group,  a  global  end  to  end  textile  and  apparel 
manufacturing leader. 
Leading denim producer Orta also manufactured sample denim fabrics containing the Company’s Nullarbor-20 fibre and 
demonstrated  the  ability  to  convert  some  of  the  fabric  into  pairs  of  jeans.  Orta  is  a  leader  in  the  development, 
manufacture  and  supply  of  sustainable  denim  and  supplies  to major  fashion  brands,  with  a total  annual  production 
capacity of 40 million metres of denim.  
In  March  2023,  Nanollose  extended  its  collaboration  agreement  with  multinational  rayon  fibre  manufacturing 
conglomerate  Grasim  Industries  Limited  for  a  further  two  years.  The  extension  served  to  validate  the  commercial 
potential from work carried out to date with Grasim business unit, Birla Cellulose.  
The fibre from the second pilot production spin has since been shipped to Nanollose’s textile manufacturing partner, 
Paradise Textiles, for conversion into yarns and fabrics. Samples of the fabrics made from the first pilot spin have also 
been sent to several fashion brands for appraisal, with unanimously positive feedback. 
Vegan leather prototype 
During the June 2023 quarter, Nanollose continued its progress towards developing a collection of commercially viable 
plastic-free ‘vegan leather’ materials, based on the Company’s microbial cellulose technology.  
Recent developments were highlighted by a successful bespoke project with Prague Design Agency IMMINENT and 181-
year-old  Czech  Republic  brewery  Pilsner  Urquell,  which  involved  Nanollose  producing  vegan  leather  material  by 
fermenting Pilsner Urquell beer. The material was then used to make an haute couture dress, designed by leading Czech 
fashion designer Jakub Polanka.  
The dress was the centrepiece of a Pilsner Urquell promotional campaign at the 57th Karlovy Vary International Film 
Festival (30th June – 8th July 2023). New and improved vegan leather prototypes have already been produced and the 
Company looks forward to providing more updates as new collaboration opportunities progress. 
Intellectual Property Update: 
Method for Dewatering Microbial Cellulose 
In May 2023, Nanollose filed a new provisional patent application with IP Australia entitled ‘Method for Dewatering 
Microbial  Cellulose’.  The  application  covers  a  novel  methodology  for  drying  microbial  cellulose  while  retaining  the 
material’s ability to reabsorb over 100 times its weight in water when rehydrated. This technology dramatically reduces 
shipping, handling, and storage costs, a key breakthrough for the commercial development of the Company’s Jelli Grow 
product. 
Jelli Grow technology is additional to and separate from the Company’s core Nullarbor fibre technology, which continues 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
to  progress  well  in  development  with  major  commercial  partners.  Prior  to  the  end  of  the  financial  year,  Nanollose 
commenced  a  technology  transfer  programme  with  its  microbial  cellulose  supply  partner,  Hainan  Guangyu 
Biotechnology, to produce a pilot batch of the new dry powder formulation of Jelli Grow to optimise the process for 
commercial-scale manufacture.  
US patent secured for sustainable fibre technology 
During the March quarter, Nanollose secured its first US granted patent, with confirmation of approval by the United 
States Patent and Trademark Office (USPTO) for the patent titled ‘Methods For Producing a Viscose Dope from Microbial 
Cellulose’ (US Patent Number 11,597,779) (the ‘Patent’). This was also the Company’s first granted patent relating to its 
fibre technology.  
The Patent covers the pulping of microbial cellulose for use in the production of viscose fibres. While the Company's 
primary focus is currently on the development of its Tree-Free Nullarbor lyocell process, the US patent is validation of 
Nanollose’s  strategy  to  establish  a  broader  leadership position in  sustainable  fibre  technologies.  It  also  expands  the 
Company’s IP footprint across its product suite and provides protection from potential competitors in the world’s largest 
consumer market. 
Nova Institute’s Cellulose Fibre Innovation of the Year Award 
During  the  March  quarter,  Nanollose  and  Birla  Cellulose’s  Nullarbor  fibre  was  recognised  by  the  receipt  of  the 
prestigious Cellulose Fibre Innovation of the Year Award 2023, which was awarded by leading private and independent 
research group,  nova-institut GmbH. The  Company was  awarded  the  prestigious  honour  at  the  2023  Cellulose  Fibre 
Conference in Cologne, Germany following a poll of conference delegates. 
Extended cooperation agreement with Codi International BV  
Earlier  in  the  year  during  the  September  quarter,  Nanollose  extended  its  partnership  with  Codi  International  BV,  a 
division of the European multinational Codi Group, for an additional three years. The agreement was set out to provide 
additional time to progress the development of wet wipes incorporating the Company’s Tree-Free rayon fibres. Codi is 
a leader in European market for high quality, sustainable wet wipes. Its clients include global brands, European retailers, 
distributors and institutional parties.  
The group distributes products to over 40 countries and owns high value proprietary technical information focused on 
the production, marketing and distribution of consumer wipes. Nanollose initially provided Codi with a sample of its 
Tree-Free Nufolium™ viscose fibre, which was then converted into a nonwoven fabric, a precursor to wet wipes. While 
the outcome of this trial was very positive, Nanollose has since transitioned from viscose to the more environmentally 
friendly lyocell version of its Nufolium fibre. 
CelluAir 
The Company was advised during the year that advanced filtration technology company, CelluAir Pty Ltd ("CelluAir”), in 
whom the Company has an ~19% interest, has elected not to proceed with its nanocellulose filtration material project, 
and to wind up the operations of the company. Nanollose assessed the carrying value of its investment in CelluAir as at 
31 December 2022, at which time it determined that the book value be written down to zero. As such, this write off was 
already reflected in the Company’s half year accounts to 31 December 2022. As part of the wind-up process, Nanollose 
expects to receive a cash payment, and has taken receipt of certain equipment owned by CelluAir which will be of use 
to Nanollose going forward. 
IMPACT OF COVID-19 GLOBAL PANDEMIC 
There  were  no  significant  impacts  on  Nanollose's  business  operations  resulting  from  the  Coronavirus  (COVID-19) 
pandemic in FY2023. 
SIGNIFICANT CHANGES IN STATE OF AFFAIRS 
Other than as detailed in the review of operations, there were no other significant changes in the state of affairs of the 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  7 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Company during the financial year. 
MATTERS SUBSEQUENT TO THE END OF THE FINANCIAL YEAR 
No matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the 
Company's operations, the results of those operations, or the Company's state of affairs in future financial years. 
OUTLOOK 
The Company has made significant progress over the past year, developing a pipeline of sustainable fibres, fabrics and 
other materials based on its microbial cellulose technologies. 
The Company continues to actively work with collaboration partners towards development of denim and other textiles 
using the Company’s Nullarbor fibres, and further refinement of the Company’s fibre products to facilitate potential 
commercial supply. These collaboration agreements provide multiple reference points and catalysts for further uptake 
from global fashion brands. Ongoing discussions are being held with additional potential partners. 
Fibre from the Company’s recent second pilot spin is currently being made into yarns and textiles. Nanollose expects to 
use some of this material for development projects with new and existing partners, but also expects that some will be 
used to make a small number of commercial garments. 
Work is ongoing towards completion of the third pilot spin with Birla Cellulose at increased scale, which will provide 
further valuable technical information and additional material for projects with existing collaborators and new partners. 
During  the  year,  Nanollose  added  two  exciting  projects  to its  development  pipeline  and  these  are  both expected  to 
provide  significant  and  diversified  opportunities  for  the  Company  in  the  coming  year.  Nanollose's  'vegan  leather' 
material,  while  still  requiring  further  research,  is  progressing  well.  The  Company  envisages  some  prototypes  to  be 
released  to  potential  partners  this  year.  In  May  2023,  Nanollose  filed  a  patent  application  for  a  new  dry  powder 
formulation of its Jelli Grow seed raising medium. This new formulation overcomes the previous challenges of shipping 
and handling, which beset the previous wet formulation. The Company is now working towards commercialising Jelli 
Grow and expects to launch it on the horticultural market later this year. 
While the diversification of the Company's product pipeline reduces some market risks, all products rely on the large-
scale production of microbial cellulose at competitive prices. This is particularly true for the fibre market and so there 
remains the risk that the Company cannot achieve the required volume and price required to attract significant sales in 
that market. 
Other risks the Company and companies of this nature manage include, maintaining its good relationships with its key 
partners in India and China, managing supply chain issues and potential delays associated with the supply chain, risks 
associated  with commercialising  disruptive  technology and  key  person  risks  managing  its  continued  access  to highly 
skilled research and development staff.  
In relation to the Company’s ESG positioning, the Company has identified that it is exposed to certain environmental 
and  social  sustainability  risks  in  respect  of  its  supply  chains  and  partner  manufacturing  processes,  parts  of  which 
originate  from  or  are conducted  overseas. The  Company  is  committed  to  sustainability  and  ethical  practices,  and is 
looking to play a leadership role in using industrial organic and agricultural waste products, and supporting supply chain 
solutions and manufacturing partners that promote responsible environmental and ethical practices, and the protection 
of  global  ecosystems.  The  Company  has  adopted  an  Ancient  Forest  Friendly  Sourcing  Policy  which  sets  out  the 
Company’s policy and processes employed to mitigate the major environmental risks associated with its business. The 
Company  is  cognisant  of  the  need  to  ensure  that  its  overseas  suppliers  and  partners  are  committed  to  ethical 
employment practices. 
AGM 
The Company anticipates that it will hold its next Annual General Meeting (‘AGM’) on or before 24 November 2023. In 
accordance with ASX Listing Rule 3.13.1, the closing date for the receipt of nominations from persons wishing to be 
considered for election as a director of the Company is 6 October 2023 (35 business days prior to the date of the AGM). 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  8 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Any  nominations  must  be  received  in  writing  no  later  than  5.00pm  (WST)  on  6  October  2023,  at  the  Company’s 
registered office. 
ENVIRONMENTAL REGULATION 
The Company is not subject to any significant environmental regulation under Australian Commonwealth or State law. 
BOARD OF DIRECTORS 
Wayne Best – Executive Chairman 
Experience and 
Expertise 
Dr Best has 40 years’ experience in organic chemistry both in academia, government and 
industry. Wayne obtained his BSc (Hons) and PhD in Organic Chemistry from The University 
of Western Australia. He then spent two years at Imperial College in the UK where he 
obtained a DIC, followed by a year at the Australian National University in Canberra. He 
then took up a position with ICI Australia’s Research Group in Melbourne for four and a half 
years which included a secondment to ICI Agrochemicals in the UK. Following ICI, Wayne 
returned to Western Australia and spent ten years at the Chemistry Centre (WA) where he 
was responsible for the formation and running of the Medicinal & Biological Chemistry 
Section which undertook collaborative R&D into drug discovery and contract synthesis for 
the drug discovery and pharmaceutical industries. He then founded Epichem Pty Ltd, a 
contract research and drug discovery Company, which he managed for 14 years before 
moving full-time to Nanollose in 2018. Wayne is a Fellow of the Royal Australian Chemical 
Institute and has held appointments as an Adjunct Associate Professor at both Murdoch 
University and The University of Western Australia. He is also a Graduate Member of the 
Australian Institute of Company Directors and has served as a Director for several listed and 
unlisted biotechnology companies. 
BSc (Honours), PhD, DIC, FRACI, GAICD 
Other Current 
Directorships 
None 
Former Directorships 
in last 3 years 
None 
Special 
Responsibilities  
Interests in Shares 
and Options 
Executive Chairman of the Board 
8,700,000 ordinary shares 
1,000,000 unlisted $0.10 options expiring 13 December 2024 
1,000,000 Class E performance rights  
Winton Willesee – Non-Executive Director 
Experience and 
Expertise 
Mr Willesee is an experienced company director with over 20 years’ experience in various 
roles within the Australian capital markets. 
Mr Willesee has considerable experience with ASX listed and other companies over a broad 
range  of  industries  having  been  involved  with  many  successful  ventures  from  early  stage 
through to large capital development projects.  
He has a core expertise in strategy, company development, corporate governance, company 
public listings, merger and acquisition transactions and corporate finance. 
Mr Willesee holds a Master of Commerce, a Post-Graduate Diploma in Business (Economics 
and Finance), a Graduate Diploma in Applied Finance and Investment, a Graduate Diploma in 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  9 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Applied Corporate Governance, a Graduate Diploma in Education and a Bachelor of Business. 
He is a Fellow of the Financial Services Institute of Australasia, a Graduate of the Australian 
Institute of Company Directors, a Member of CPA Australia and a Fellow of the Governance 
Institute of Australia and the Institute of Chartered Secretaries and Administrators/Chartered 
Secretary. 
BBus, DipEd, PGDipBus, MCom, FFin, CPA, GAICD, FGIS/FCIS 
Other Current 
Directorships 
Non-Executive Director of One Click Group Limited (ASX:1CG) (formerly UUV Aquabotix Ltd 
(ASX:UUV)) (appointed 3 October 2020) 
Non-Executive Director of Neurotech International Limited (ASX: NTI) (appointed 15 April 
2019) 
Non-Executive Director of Bridge SaaS Limited (ASX:BGE) (appointed 5 May 2023) 
Non-Executive Director of Metals One Plc (AIM:MET1) (appointed 25 July 2023) 
Non-Executive Chairman of Citius Resources PLC (LSE:CRES) (appointed November 2020) 
Former Directorships 
in last 3 years 
Non-Executive Director of eSense Lab Ltd (from 31 July 2020 to 21 September 2021) 
(delisted from ASX on 10 August 2021) 
Non-Executive Director of Hygrovest Ltd (ASX: HGV) (from 21 October 2014 to 20 March 
2023) 
Non-Executive Chairman of New Zealand Coastal Seafoods Limited (ASX:NZS) (from 7 July 
2016 to 10 March 2023) 
Interests in Shares 
and Options 
8,068,504 ordinary shares 
500,000 unlisted $0.147 options expiring 7 December 2024 
Terence Walsh – Non-Executive Director 
Experience and 
Expertise 
Mr Walsh is a senior commercial lawyer and manager with more than 20 years of experience 
in project development, mining and general commercial law.  He initially worked with leading 
law firms in Perth and Sydney before moving in house, where he has worked as the General 
Counsel of Hancock Prospecting Pty Ltd and prior to that as a Corporate Counsel with Rio Tinto 
Ltd.  In these roles he has been involved with the legal and commercial aspects associated with 
the development and operation of technology and mining projects.   
Other Current 
Directorships 
None 
Former Directorships 
in last 3 years 
Non-Executive Director of Structural Monitoring Systems PLC (ASX:SMN) (from 11 April 2018 
to 14 October 2020) 
Interests in Shares 
and Options 
965,672 ordinary shares 
500,000 unlisted $0.147 options expiring 7 December 2024 
Heidi Beatty – Non-Executive Director  
Experience and 
Expertise 
Heidi  Beatty,  founder  of  Crown  Abbey  Ltd  is  a  scientist  and  innovator  who  has  20  years’ 
experience developing consumer and health care products.  After gaining a BSc in Chemistry 
from the University of York UK, Heidi worked with Johnson & Johnson for 10 years in Europe 
and the US.  In 2015 Heidi founded Crown Abbey Ltd, a consultancy company that supports 
clients in their project launches, combining Project Management and Product Development 
across Consumer and Healthcare categories 
Other Current 
None 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  10 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Directorships 
Former Directorships 
in last 3 years 
None 
Interests in Shares 
and Options 
68,504 ordinary shares 
500,000 unlisted $0.08 options expiring 31 October 2023 
JOINT COMPANY SECRETARIES 
Erlyn Dawson – Joint Company Secretary  
Experience and 
Expertise 
Mrs  Dawson  is  an  experienced  corporate  professional  with  a  broad  range  of  corporate 
governance  and  capital  markets  experience,  having  been  involved  with  several  public 
company  listings,  merger  and  acquisition  transactions  and  capital  raisings  for  ASX-listed 
companies across a diverse range of industries.   
Mrs Dawson began her career in corporate recovery and restructuring at Ferrier Hodgson 
and  is  now  the  Managing  Director  of  corporate  services  firm,  Azalea  Consulting,  which 
provides  outsourced  company  secretarial,  accounting  and  administration  services  to  a 
portfolio of ASX-listed companies.  
Mrs  Dawson  holds  a  Bachelor  of  Commerce  (Accounting  and  Finance)  and  a  Graduate 
Diploma in Applied Corporate Governance. She is a member of the Governance Institute of 
Australia/Chartered Secretary. 
Emily Spano – Joint Company Secretary  
Experience and 
Expertise 
Ms Spano is an experienced corporate professional, with significant knowledge of corporate 
law, capital markets and corporate governance.  
She  has  extensive  experience  as  a  corporate lawyer  and a  consultant advising  ASX listed 
companies on a variety of transactions including capital raisings, mergers and acquisitions, 
ASX listings and ASX compliance.  
Ms Spano holds a Bachelor of Law and a Bachelor of Commerce (Finance) and is a graduate 
of the Australian Institute of Company Directors. 
DIRECTORS’ MEETINGS 
Attendances by each Director during the year were as follows: 
Director 
Wayne Best 
Winton Willesee 
Terence Walsh 
Heidi Beatty 
Number 
Eligible to 
Attend 
Number 
Attended 
6 
6 
6 
6 
6 
6 
6 
6 
Eligible: represents the number of meetings held during the time the director held office. 
NANOLLOSE LIMITED ANNUAL REPORT 2023  
PAGE  11 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
REMUNERATION REPORT (AUDITED) 
The  remuneration  report  details  the  key  management  personnel  remuneration  arrangements  for  the  Company,  in 
accordance with the requirements of the Corporations Act 2001 and its Regulations. 
Key management personnel are those persons having authority and responsibility for planning, directing and controlling 
the activities of the Company, directly or indirectly, including all directors. 
The remuneration report is set out under the following main headings: 
● 
● 
● 
● 
● 
Principles used to determine the nature and amount of remuneration 
Details of remuneration 
Service agreements 
Share-based compensation 
Additional disclosures relating to key management personnel 
Principles used to determine the nature and amount of remuneration 
The objective of the Company’s executive reward framework is to ensure reward for performance is competitive and 
appropriate  for  the  results  delivered.  The  framework  aligns  executive  reward  with  the  achievement  of  strategic 
objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for 
the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key 
criteria for good reward governance practices: 
● 
● 
● 
● 
competitiveness and reasonableness 
acceptability to shareholders 
performance linkage / alignment of executive compensation 
transparency 
The  Board,  fulfilling  the  role  of  the  Nomination  and  Remuneration  Committee,  is  responsible  for  determining  and 
reviewing remuneration arrangements for its directors and executives. The performance of the Company depends on 
the  quality  of  its  directors  and  executives.  The  remuneration  philosophy  is  to  attract,  motivate  and  retain  high 
performance and high-quality personnel. 
The Board has structured an executive remuneration framework that is market competitive and complementary to the 
reward strategy of the Company. 
The reward framework is designed to align executive reward to shareholders' interests. The Board have considered that 
it should seek to enhance shareholders' interests by: 
● 
● 
having value creation and capital growth in advance of economic profit as a core component of plan design; 
focusing  on  sustained  growth  in  shareholder  wealth,  consisting  of  growth  in  share  price  and  eventually 
dividends, and delivering constant or increasing return on assets as well as focusing the executive on key non-
financial drivers of value; and 
● 
  attracting and retaining high calibre executives. 
Additionally, the reward framework should seek to enhance executives' interests by: 
● 
● 
● 
  rewarding capability and experience; 
  reflecting competitive reward for contribution to growth in shareholder wealth; and 
 providing a clear structure for earning rewards. 
In accordance with best practice corporate governance, the structure of non-executive director and executive director 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
                   PAGE  12 
 
 
  
  
 
  
 
DIRECTORS’ REPORT 
remuneration is separate. 
Non-executive directors’ remuneration 
Fees  and  payments  to  non-executive  directors  reflect  the demands  and  responsibilities  of  their role.  Non-executive 
directors'  fees  and  payments  are reviewed  from  time  to time  by  the Board fulfilling  its role  as  the  Nomination  and 
Remuneration  Committee.  The  Board  may,  from  time  to  time,  receive  advice  from  independent  remuneration 
consultants  to ensure  non-executive  directors'  fees  and  payments  are  appropriate  and in line  with  the market. The 
chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles 
in the external market. The chairman is not entitled to vote on the determination of his own remuneration. Given the 
nature of the Company and the more hands-on role the non-executive directors’ play in the operations of the Company 
non-executive directors may receive share options or other incentives. 
The ASX Listing Rules and the Company’s Constitution provide that the aggregate annual non-executive directors' fees 
paid shall not exceed that determined by shareholders in a general meeting. The most recent determination was via a 
resolution  of  all  shareholders  on  5  June  2016,  where  the  shareholders  approved  a  maximum  annual  aggregate 
remuneration of $500,000. 
Executive directors’ remuneration 
The Company aims to reward executives based on their position and responsibility, with a level and mix of remuneration 
which has both fixed and variable components. 
 The executive remuneration and reward framework has four components: 
● 
● 
● 
● 
  base pay and non-monetary benefits 
  short-term performance incentives 
  share-based payments 
  other remuneration such as superannuation and long service leave 
The combination of these comprises the executive's total remuneration. 
Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed regularly by 
the  Board  fulfilling  the  role  of  Nomination  and  Remuneration  Committee  based  on  the  overall  performance  of  the 
Company and comparable market remunerations. 
Executives may  receive  their  fixed  remuneration  in  the  form  of  cash  or  other  benefits  where  it  does  not create any 
additional costs to the Company and provides additional value to the executive. 
The short-term incentives ('STI') program has yet to be finalised. Once adopted it will be designed to align the targets of 
the Company with the performance hurdles of executives. STI payments will be granted to executives based on specific 
annual targets and key performance indicators ('KPI's') being achieved.   
The long-term incentives ('LTI') include equity-based payments. Equity securities are awarded to executives with vesting 
conditions  and  expiry  dates  aligned  to  the  Company’s  business  plans  and  targets. The  details  of  the  current vesting 
conditions and targets are as follows and further detailed in the section on service agreements found below.  
Options 
The are no unvested options currently on issue as at the date of this report. 
Performance Rights 
On 13 December 2022 following shareholder approval on 25 November 2022, the Company issued 1,000,000 Class E 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  13 
 
  
DIRECTORS’ REPORT 
Performance Rights to Dr Wayne Best.  The Class E Performance Rights are to vest on the achievement of either of the 
following milestones on or before 13 December 2024:  
A. 
B. 
The Company commissions and completes the construction of a plant with capacity to produce more than 10 
tonnes per month of microbial cellulose.  
Takeover:  A  Take  Over Event  occurs.  A  “Takeover Event” means  a  takeover  bid  for  the  Company  pursuant  to 
Chapter 6 of the Corporations Act where the bidder achieves control of more than 50% of the ordinary shares by 
shareholders accepting the bid or a court grants an order approving a compromise or scheme where the ordinary 
shares  are  either  cancelled  or  transferred  to  third  party  (not  being  a  scheme  of  arrangement  simply  for  the 
purpose of corporate restructure).   
Company performance and link to remuneration 
Remuneration  for  certain  individuals  is  directly  linked  to  the  performance  of  the  Company.  Each  key  management 
personnel  held  equity  securities  designed  to  incentivise  them  to  drive  the  Company’s  performance  in  line  with  its 
business plans.  
A portion of any cash bonus that may be paid to executives will be directly linked to the achievement of goals designed 
to align with the Company’s performance. 
Details of remuneration 
Details of the remuneration of key management personnel of the Company during the year ended 30 June 2023 are set 
out in the following tables. 
The key management personnel of the Company consisted of the following directors of Nanollose Limited: 
Directors 
Wayne Best 
Winton Willesee 
Terence Walsh 
Heidi Beatty 
Executive Chairman  
Non-Executive Director 
Non-Executive Director 
Non-Executive Director  
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  14 
 
 
 
DIRECTORS’ REPORT 
Key Management Personnel Compensation 
The compensation of the Company’s Key Management Personnel is disclosed below: 
Cash Salary 
and fees  
Super- 
annuation 
Annual 
Leave  
Options 
issued 
Equity-
settled 
Shares  
Equity-
settled 
Performance 
rights 
Total 
Fixed 
Incentive 
($) 
($) 
($) 
($) 
($) 
($) 
($) 
(%) 
(%) 
2023 Key 
Management 
Personnel 
DIRECTORS 
Executives: 
Wayne Best 
225,000 
23,625 
15,970 
         34,640 
Non-executives: 
Winton Willesee 
 35,000 
Terence Walsh 
 35,000 
Heidi Beatty 
35,000 
          - 
          - 
         - 
             - 
                - 
             - 
                - 
             - 
          - 
TOTAL 
330,000 
23,625 
15,970 
    34,640 
- 
- 
- 
-        
- 
 21,729 
320,964 
82% 
18% 
          - 
          - 
          - 
35,000 
35,000 
35,000 
21,729 
425,964 
100% 
100% 
100% 
- 
- 
- 
NANOLLOSE LIMITED ANNUAL REPORT 2022 
                   PAGE  15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Cash Salary 
and fees  
Super- 
annuation 
Annual 
Leave  
Options 
issued 
Equity-
settled 
Shares  
Equity-
settled 
Performance 
rights 
Total 
Fixed 
Incentive 
($) 
($) 
($) 
($) 
($) 
($) 
($) 
(%) 
(%) 
2022 Key 
Management 
Personnel 
DIRECTORS 
Executives: 
Wayne Best 
225,000 
22,669 
18,213 
         - 
Non-executives: 
Winton Willesee 
 35,000 
Terence Walsh 
 35,000 
Heidi Beatty 
35,000 
          - 
          - 
         - 
             - 
      42,600 
             - 
      42,600 
             - 
          - 
TOTAL 
330,000 
22,669 
18,213 
85,200 
- 
- 
- 
-        
- 
 (65,835) 
200,047 
100% 
          - 
          - 
          - 
77,600 
77,600 
35,000 
(65,835) 
390,247 
45% 
45% 
100% 
- 
- 
55% 
55% 
- 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Service Agreements 
Remuneration and other terms of employment for key management personnel are formalised in service agreements. 
Details of these agreements are as follows: 
Name: 
Title: 
Agreement commenced: 
Term of agreement: 
Details: 
Wayne Best 
Executive Chairman 
10 April 2018 
No fixed term 
The  remuneration  of  Dr  Wayne  Best  is  $225,000  per  year  plus  statutory 
superannuation.  
Key management personnel have no entitlement to termination payments in the event of removal for misconduct. 
Share-based compensation 
On 25 November 2022, Shareholders agreed to issue the following performance rights and options to Directors: 
On 13 December 2022, Dr Wayne Best was issued 1,000,000 Class E Performance Rights. The Performance Rights vest 
on the achievement of certain milestones by 13 December 2024 and upon vesting, each Class E Performance Right will 
be convertible into one ordinary share at the election of the holder. An expense of $21,729 was recognised in the 
financial year ended 30 June 2023. 
Number of performance rights 
Grant date 
Vesting date 
Share price at grant date 
Probability of vesting 
1,000,000 
25 Nov 2022 
13 Dec 2024 
$0.075 
100% 
Issue of 1,000,000 Class K options (NC6OPT7 $0.10 expiry 13 December 2024) to Wayne Best valued at $34,640. 
The options were valued using the Hoadley ESO2 Valuation model using the following assumptions: 
Strike price: 
Stock price: 
Expiry date: 
Risk free rate: 
Volatility: 
Dividend yield:  nil 
$0.10 
$0.075 
13 December 2024 
3.19% 
100% 
Additional information 
The loss of the Company for the five years to 30 June 2023 are summarised below: 
Sales revenue 
EBITDA 
EBIT 
Loss after income tax 
2023 ($) 
     38,101 
(1,324,799) 
(1,361,568) 
(1,345,656) 
2022 ($) 
- 
(1,505,105) 
(1,570,109) 
(1,566,504) 
2021 ($) 
- 
(875,938) 
(932,885) 
(931,045) 
2020 ($) 
- 
(1,187,793) 
(1,241,318) 
(1,235,489) 
2019 ($) 
- 
(2,022,299) 
(2,054,457) 
(2,003,995) 
The factors that are considered to affect total shareholders return ('TSR') are summarised below.  
Share price at financial year end ($)  
Total dividends declared (cents per share) 
2023 
0.055 
- 
2022 
0.071 
- 
2021 
0.09 
- 
2020 
0.04 
- 
2019 
0.05 
- 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
                   PAGE  17 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Basic loss per share (cents per share) 
0.90 
1.05 
0.77 
1.57 
2.67 
Additional disclosures relating to key management personnel 
Shareholdings 
The  number  of  shares  in  the  Company  held  during  the  financial  year  by  each  director  and  other  members  of  key 
management personnel of the Company, including their personally related parties, is set out below: 
Balance at 
the start of 
the year 
Received 
as part of 
remuneration 
  8,431,798 
  8,068,504 
      965,672 
        68,504 
17,534,478 
- 
- 
- 
- 
- 
Disposal on 
resignation 
Balance at 
the end of 
the year 
- 
-  
- 
- 
- 
           8,700,000 
           8,068,504 
              965,672 
                68,504 
        17,802,680 
Additions 
268,202 
- 
- 
- 
268,202 
Ordinary shares 
Wayne Best 
Winton Willesee 
Terence Walsh 
Heidi Beatty 
Total 
Option holdings 
The number of options over ordinary shares in the Company held during the financial year by each director and other 
members of key management personnel of the Company, including their personally related parties, is set out below: 
Balance at  
the start of  
the year 
Issued 
Exercised 
Expired/  
disposal on  
 resignation 
Balance at  
the end of  
the year 
                      - 
            500,000 
            500,000 
            500,000 
       1,000,000                
                      - 
                      - 
                      - 
             - 
             - 
             - 
             - 
         1,500,000 
      1,000,000 
             - 
             - 
             - 
             - 
             - 
             - 
         1,000,000                
            500,000 
            500,000 
            500,000 
         2,500,000 
Options over ordinary shares 
Wayne Best 
Winton Willesee 
Terence Walsh 
Heidi Beatty 
Total 
Performance Rights holdings 
The number of performance rights in the Company held during the financial year by each director and other members 
of key management personnel of the Company, including their personally related parties, is set out below: 
Rights to Ordinary shares 
Wayne Best 
Total 
Balance at 
the start of 
the year 
Issued 
Converted 
Expired/ 
forfeited/ 
other 
- 
- 
1,000,000 
1,000,000 
-  
- 
-  
- 
Balance at 
the end of 
the year 
1,000,000 
1,000,000 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  18 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
             
 
 
 
  
 
  
  
 
  
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
Other transactions with key management personnel and their related parties during the financial year 
(i) Receivable from and payable to key management personnel and their related parties are as follows: 
The following balances are outstanding at the reporting date in relation to transactions with key management personnel 
and their related parties: 
Payable to Azalea Accounting Services Pty Ltd (director related entity of Winton Willesee) 
Payable to Azalea Corporate Services Pty Ltd (director related entity of Winton Willesee) 
(ii) Transactions with key management personnel and their related parties 
2023 
- 
10,412 
2022 
2,000 
5,496 
Payments to Azalea Accounting Services Pty Ltd (director related entity of Winton Willesee) of Nil (2022: $22,000) for 
bookkeeping and financial reporting services fees. 
Payments to Azalea Corporate Services Pty Ltd (director related entity of Winton Willesee) of $82,451 (2022: $60,451) 
for bookkeeping and financial reporting services fees, corporate services fees including company secretarial services, 
and front and registered office services. 
All transactions were made on normal commercial terms and conditions and at market rates. 
Voting and comments made at the Company's 2022 Annual General Meeting ('AGM') 
At the AGM held on 25 November 2022, the Company received votes representing 28,403,303 shares in favour of the 
adoption of the remuneration report put to shareholders for the financial year ended 30 June 2022.  This represented 
82.85% of the votes cast on that resolution. 
This is the end of the Audited Remuneration Report. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT 
SHARES 
As at the date of this report, there are 148,886,368 (2022: 148,886,368) fully paid ordinary shares on issue. 
Options on issue 
Unissued ordinary shares of Nanollose Limited under option as at the date of this report are as follows: 
Date of issue 
Class of option 
No. of Options 
Exercise price 
                 Expiry date 
  4 December 2020 
  20 April 2021 
  5 July 2021 
  15 September 2021 
  7 December 2021 
  13 December 2022 
  20 January 2023 
   Total 
Class G 
Class H 
NC6OA 
Class I 
Class J 
Class K 
Class L 
           500,000 
         $0.08 
31 October 2023 
        1,000,000 
         $0.10 
        20 April 2024 
22,268,635 
$0.15 
        5 July 2024 
1,000,000 
1,000,000 
1,000,000 
500,000 
        27,268,635 
$0.15 
    15 September 2024 
$0.147 
 7 December 2024 
         $0.10 
       13 December 2024 
         $0.10 
        20 January 2026 
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share 
issue of the Company or of any other body corporate. 
Performance Rights on issue 
1,000,000 Class E Performance Rights were issued to Dr Wayne Best on 13 December 2022. The Performance 
Rights vest on the achievement of certain milestones by 13 December 2024.  
Indemnity and insurance of officers 
The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity 
as a director or executive, for which they may be held personally liable, except where there is a lack of good 
faith. 
During  the  financial  year,  the  Company  paid  a  premium  in  respect  of  a  contract  to  insure  the  directors  and 
executives of the Company against a liability to the extent permitted by the Corporations Act 2001. The contract 
of insurance prohibits disclosure of the nature of the liability and the amount of the premium. 
Proceedings on behalf of the Company  
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings 
on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose 
of taking responsibility on behalf of the Company for all or part of those proceedings. 
Indemnity and insurance of auditor 
The  Company  has  not,  during  or  since  the  end  of  the  financial  year,  indemnified  or  agreed  to indemnify  the 
auditor of the Company or any related entity against a liability incurred by the auditor. 
During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of 
the Company or any related entity. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  20 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIRECTORS’ REPORT   NANOLLOSE LIMITED ANNUAL REPORT 2023 PAGE  21 Non-audit services Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in Note 16 to the financial statements.  The directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.  The directors are of the opinion that the services as disclosed in Note 16 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:  • all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and • none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.  Officers of the company who are former partners of RSM Australia Partners There are no officers of the company who are former partners of RSM Australia Partners. Corporate Governance  The Company’s 2023 Corporate Governance Statement is contained in the ‘Corporate Governance’ section of the Company’s website at https://nanollose.com/about/corporate-governance/.  Auditor  RSM Australia Partners continues in office in accordance with Section 327 of the Corporations Act 2001.  Auditor’s Independence Declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' Report.  This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.  Signed on behalf of the Board of Directors.  Winton Willesee Non-Executive Director Dated at Perth, Western Australia 28 August 2023  Level 32 Exchange Tower, 2 The Esplanade Perth WA 6000 
GPO Box R1253 Perth WA 6844 
RSM Australia Partners 
T +61 (0) 8 9261 9100 
F +61 (0) 8 9261 9111 
www.rsm.com.au 
AUDITOR’S INDEPENDENCE DECLARATION 
As  lead  auditor  for  the  audit  of  the  financial  report  of  Nanollose  Limited  for  the  year  ended  30  June  2023,  I 
declare that, to the best of my knowledge and belief, there have been no contraventions of: 
(i) 
(ii) 
the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and 
any applicable code of professional conduct in relation to the audit. 
RSM AUSTRALIA PARTNERS 
Perth, WA 
Dated: 28 August 2023 
ALASDAIR WHYTE 
Partner 
THE POWER OF BEING UNDERSTOOD 
AUDIT | TAX | CONSULTING 
RSM Australia Partners is a member of the RSM network and trades as RSM.  RSM is the trading name used by the members of the RSM network.  Each member of the RSM network is an independent 
accounting and consulting firm which practices in its own right.  The RSM network is not itself a separate legal entity in any jurisdiction. 
RSM Australia Partners ABN 36 965 185 036 
Liability limited by a scheme approved under Professional Standards Legislation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 
FOR THE YEAR ENDED 30 JUNE 2023 
Notes 
30 June 2023 ($) 
30 June 2022 ($) 
Revenue 
Sales 
Interest income 
R&D incentives 
Expenses 
Research expenses 
38,101 
17,100 
- 
6,563 
      374,063 
      224,611 
429,264 
231,174 
(353,875) 
(448,164) 
Promotion and communication expenses 
     (185,132) 
     (253,278) 
Consultancy and legal expenses 
Employee benefits expense 
     (74,099) 
     (67,969) 
     (648,702) 
     (646,760) 
Depreciation and amortisation                                                                                                                       
(36,769) 
(65,004) 
Share-based payments                         
13 
    (68,969) 
    (71,765) 
Share of losses of associates using the equity accounting 
method 
Other expenses 
Interest expense 
Impairment of Investment 
Fixed asset disposal 
Foreign exchange losses 
(LOSS) BEFORE INCOME TAX 
Income tax benefit 
(LOSS) AFTER INCOME TAX 
Other comprehensive income/(loss) 
Total comprehensive (loss) for the year 
Basic loss per share (cents per share)  
Diluted loss per share 
- 
(16,356) 
     (214,875) 
     (224,897) 
         (1,188) 
         (2,958) 
(160,199) 
(30,698) 
(414) 
- 
- 
(527) 
     (1,345,656) 
     (1,566,504) 
- 
- 
     (1,345,656) 
     (1,566,504) 
- 
- 
(1,345,656) 
(1,566,504) 
(0.90) 
(0.90) 
(1.05) 
(1.05) 
8 
4 
24 
24 
The Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the accompanying notes. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
STATEMENT OF FINANCIAL POSITION 
AS AT 30 JUNE 2023 
CURRENT ASSETS 
Cash and cash equivalents 
Trade and other receivables 
Prepayments 
TOTAL CURRENT ASSETS 
NON-CURRENT ASSETS 
Right of use asset 
Investments in associate 
Plant and equipment 
TOTAL NON-CURRENT ASSETS 
TOTAL ASSETS 
CURRENT LIABILITIES 
Trade and other payables 
Provisions 
Lease liability 
TOTAL CURRENT LIABILITIES 
TOTAL LIABILITIES 
NET ASSETS 
EQUITY 
Issued capital  
Reserves 
Accumulated Losses 
TOTAL EQUITY 
Notes 
30 June 2023 ($) 
30 June 2022 ($) 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
548,248 
20,452 
31,045 
599,745 
11,021 
- 
22,472 
33,493 
1,586,252 
20,406 
42,011 
1,648,669 
37,471 
160,199 
63,489 
261,159 
  633,238 
  1,909,828 
92,782 
77,305 
11,519 
88,177 
55,239 
38,093 
     181,606 
     181,509 
181,606 
451,632 
181,509 
1,728,319 
8,975,496 
1,123,395 
8,975,496 
1,054,426 
(9,647,259) 
(8,301,603) 
451,632 
1,728,319 
The Statement of Financial Position is to be read in conjunction with the accompanying notes. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2023 
Balance as at 1 July 2022 
Total comprehensive loss for the year 
Transactions with owners in their capacity as owners: 
K Class options issued (note 13a) 
Issue of class NC6OPT8 options 
E Class performance rights not vested (note 13b) 
Issued Capital ($) 
Reserves ($) 
Accumulated 
Losses ($) 
Total Equity ($) 
   8,975,496 
1,054,426 
(8,301,603) 
1,728,319 
- 
- 
- 
- 
- 
(1,345,656) 
      (1,345,656) 
34,640 
12,600 
21,729 
- 
- 
- 
34,640 
12,600 
21,729 
Balance as at 30 June 2023 
                 8,975,496 
1,123,395 
   (9,647,259) 
451,632 
The Statement of Changes in Equity is to be read in conjunction with the accompanying notes. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2022 
Balance as at 1 July 2021 
Total comprehensive loss for the year 
Transactions with owners in their capacity as owners: 
Issue of class NC6OA options 
Shares issued on exercise of F Class options  
I Class options issued (note 13a) 
J Class options issued (note 13a) 
D Class performance rights not vested (note 13b) 
Issued Capital ($) 
Reserves ($) 
Accumulated 
Losses ($) 
Total Equity ($) 
   8,955,496 
653,411 
(6,735,099) 
2,873,808 
- 
- 
20,000 
- 
- 
- 
- 
(1,566,504) 
      (1,566,504) 
329,250 
- 
52,400 
85,200 
(65,835) 
- 
- 
- 
- 
- 
329,250 
20,000 
52,400 
85,200 
      (65,835) 
Balance as at 30 June 2022 
                 8,975,496 
1,054,426 
   (8,301,603) 
1,728,319 
The Statement of Changes in Equity is to be read in conjunction with the accompanying notes. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE  26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED  
30 JUNE 2023 
CASH FLOWS FROM OPERATING ACTIVITIES 
Receipts from customers 
R&D incentive received 
Notes 
30 June 2023 ($) 
30 June 2022 ($) 
37,641 
374,063 
- 
224,611 
Payments to suppliers and employees 
(1,439,046) 
(1,610,522) 
Interest paid 
Interest received 
(1,188) 
17,100 
(2,958) 
6,563 
NET CASH USED IN OPERATING ACTIVITIES 
22 
(1,011,430)  
(1,382,306)  
CASH FLOWS FROM INVESTING ACTIVITIES 
Payments For Plant and Equipment 
Investment in associate 
NET CASH USED IN INVESTING ACTIVITIES 
CASH FLOWS FROM FINANCING ACTIVITIES 
Proceeds from issue of shares 
Payment of share issue costs 
Repayment of lease liability 
Repayment of borrowings 
Proceeds from borrowings 
- 
-     
- 
- 
(26,574) 
    - 
- 
(5,352) 
-     
(5,352) 
20,000 
- 
(26,212) 
    (26,475) 
- 
NET CASH (USED IN) / FROM FINANCING ACTIVITIES 
(26,574)     
(32,687)     
Net (decrease) / increase in cash and cash equivalents 
(1,038,004)           
(1,420,345)           
Cash and cash equivalents at beginning of financial year 
1,586,252 
3,006,597 
Cash and cash equivalents at end of financial year 
5 
548,248          
1,586,252          
The Statement of Cash Flows is to be read in conjunction with the accompanying notes.
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES 
The primary accounting policies adopted in the preparation of the Financial Statements are set out below. These 
policies have been consistently applied to all years presented, unless otherwise stated. 
New or amended Accounting Standards and Interpretations adopted 
The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the 
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. 
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early 
adopted. 
The following Accounting Standards and Interpretations are most relevant to the Company: 
a.  Basis of Preparation 
These  general-purpose  financial  statements  have  been  prepared  in  accordance  with  Australian  Accounting 
Standards  and  Interpretations  issued  by  the  Australian  Accounting  Standards  Board  ('AASB')  and  the 
Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply 
with  International  Financial  Reporting  Standards  as  issued  by  the  International  Accounting  Standards  Board 
('IASB'). 
b.  Historical cost convention 
The financial statements have been prepared under the historical cost convention, except for, where applicable, 
certain financial assets and liabilities. 
c.  Critical accounting estimates 
The  preparation  of  the  financial  statements  requires  the  use  of  certain  critical  accounting  estimates.  It  also 
requires management to exercise its judgement in the process of applying the Company’s accounting policies. 
The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are 
significant to the financial statements, are disclosed in note 2. 
Going concern 
The  financial  statements  have  been  prepared  on  the  going  concern  basis,  which  contemplates  continuity  of 
normal  business  activities  and  the  realisation  of  assets  and  discharge  of  liabilities  in  the  normal  course  of 
business. 
The Company incurred a loss of $1,345,656 and net cash outflows from operating activities of $1,011,430 for 
the financial year ended 30 June 2023.  
The  ability  of  the  Company  to  continue  as  a  going  concern  is  principally  dependent  upon  the  ability  of  the 
Company to generate sufficient cash inflows from operations, by raising additional capital from equity markets 
and managing cash flows in line with available funds.  
These factors indicate an uncertainty which may cast doubt as to whether the Company will continue as a going 
concern  and  therefore  whether  it  will  realise  its  assets  and  extinguish  its  liabilities  in  the  normal  course  of 
business and at the amounts stated in the financial report. 
The Board believes that there are reasonable grounds to believe that the Company will be able to continue as a 
going concern and that it is appropriate for it to adopt the going concern basis in the preparation of the financial 
report after consideration of following factors: 
- 
The Company expects to receive a R&D tax incentive related to its R&D activities for the year ended 30 
June 2023 upon lodgement of its claim; 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 28 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
- 
- 
The Company has the ability to issue additional equity securities under the Corporations Act 2001 to raise 
further working capital; and 
The Company has the ability to curtail administrative, discretionary research expenses and overhead cash 
outflows as and when required.  
Accordingly,  the Board believes  that  the  Company will  be able  to continue  as  a going  concern  and  that  it is 
appropriate to adopt the going concern basis in the preparation of the financial report.  
The financial report does not include any adjustments relating to the amounts or classification of recorded assets 
or liabilities that might be necessary if the Company does not continue as a going concern. 
Operating segments 
Operating segments are presented using the ‘management approach’, where the information presented is on 
the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is 
responsible for the allocation of resources to operating segments and assessing their performance. 
Foreign currency translation 
The financial statements are presented in Australian dollars, which is Nanollose Limited’s functional and 
presentation currency. 
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the 
dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions 
and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in 
foreign currencies are recognised in profit or loss.  
Revenue recognition 
The Company recognises revenue as follows:  
Revenue from contracts with customers 
Revenue is recognised at an amount that reflects the consideration to which the  Company is expected to be 
entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the 
consolidated  entity:  identifies  the  contract  with  a  customer;  identifies  the  performance  obligations  in  the 
contract; determines the transaction price which takes into account estimates of variable consideration and the 
time value of money; allocates the transaction price to the separate performance obligations on the basis of the 
relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when 
or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods 
or services promised.  
Variable consideration within the transaction price, if any, reflects concessions provided to the customer such 
as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent 
events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The 
measurement  of  variable  consideration  is  subject  to  a  constraining  principle  whereby  revenue  will  only  be 
recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue 
recognised  will  not  occur.  The  measurement  constraint  continues  until  the  uncertainty  associated  with  the 
variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle 
are recognised as a refund liability.  
Sale of goods 
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the 
goods, which is generally at the time of delivery.  
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 29 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
Interest 
Interest income is recognised as interest accrues using the effective interest method.  
Other revenue 
Other revenue is recognised when it is received or when the right to receive payment is established. 
Income tax 
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on 
the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities 
attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where 
applicable. 
Deferred  tax  assets  and  liabilities  are  recognised  for  temporary  differences  at  the  tax  rates  expected  to  be 
applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or 
substantively enacted, except for: 
● 
● 
When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset 
or liability in a transaction that is not a business combination and that, at the time of the transaction, 
affects neither the accounting nor taxable profits; or 
When the taxable temporary difference is associated with interests in subsidiaries, associates or joint 
ventures, and the timing of the reversal can be controlled, and it is probable that the temporary 
difference will not reverse in the foreseeable future. 
Deferred  tax  assets  are  recognised  for  deductible  temporary  differences  and  unused  tax  losses  only  if  it  is 
probable that future taxable amounts will be available to utilise those temporary differences and losses. 
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. 
Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits 
will  be  available  for  the  carrying  amount  to  be  recovered.  Previously  unrecognised  deferred  tax  assets  are 
recognised to the extent that it is probable that there are future taxable profits available to recover the asset. 
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax 
assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the 
same  taxable  authority  on either  the  same  taxable entity or  different  taxable entities  which intend  to  settle 
simultaneously. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 30 
 
 
 
 
 
  
 
  
 
  
 
 
  
  
  
  
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
Earnings per share 
Basic earnings per share 
Basic earnings per share is calculated by dividing the profit attributable to the owners of the Company, excluding 
any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares 
outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial 
year. 
Diluted earnings per share 
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into 
account  the  after  income  tax  effect  of  interest  and  other  financing  costs  associated  with  dilutive  potential 
ordinary shares and the weighted average number of shares assumed to have been issued for no consideration 
in relation to dilutive potential ordinary shares. 
Current and non-current classification 
Assets  and  liabilities  are  presented  in  the  statement  of  financial  position  based  on  current  and  non-current 
classification. 
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in 
the Company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised 
within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being 
exchanged  or  used  to  settle a  liability  for  at  least  12 months  after  the  reporting  period.  All  other  assets  are 
classified as non-current. 
A liability is classified as current when: it is either expected to be settled in the Company's normal operating 
cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting 
period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the 
reporting period. All other liabilities are classified as non-current. 
Cash and cash equivalents 
Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-
term, highly liquid investments with original maturities of three months or less that are readily convertible to 
known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of 
cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown 
within borrowings in current liabilities on the statement of financial position. 
Trade and other receivables 
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the 
effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for 
settlement within 30 days. 
The Company has applied the simplified approach of measuring expected credit losses, which uses a lifetime 
expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on 
days overdue. 
Other receivables are recognised at amortised cost, less any allowance for expected credit losses. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 31 
 
 
 
 
 
 
  
 
  
 
  
  
  
 
  
 
 
 
  
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATAMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
Plant and equipment 
Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost 
includes expenditure that is directly attributable to the acquisition of the items. 
Depreciation is calculated on a straight-line or diminishing balance basis to write off the net cost of each class 
of plant and equipment over their expected useful lives as follows: 
Plant and equipment 
Leasehold improvements   
3-5 years 
4 years 
diminishing balance 
straight-line  
The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each 
reporting date. 
Leasehold improvements and plant and equipment under lease are depreciated over the unexpired period of 
the lease or the estimated useful life of the assets, whichever is shorter. 
An item of plant and equipment is derecognised upon disposal or when there is no future economic benefit to 
the Company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or 
loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits. 
Right-of-use assets 
A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at 
cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments 
made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, 
and,  except  where  included  in  the  cost  of  inventories,  an  estimate  of  costs  expected  to  be  incurred  for 
dismantling and removing the underlying asset, and restoring the site or asset. 
Right-of-use  assets  are  depreciated  on  a  straight-line  basis  over  the  unexpired  period  of  the  lease  or  the 
estimated useful life of the asset, whichever is the shorter. Where the Company expects to obtain ownership of 
the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets 
are subject to impairment or adjusted for any remeasurement of lease liabilities. 
The Company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term 
leases  with  terms  of  12  months  or  less  and  leases  of  low-value  assets.  Lease  payments  on  these  assets  are 
expensed to profit or loss as incurred. 
Research and development 
Research costs are expensed in the period in which they are incurred.  Development costs are capitalised when 
it  is  probable  that  the  project  will  be  a  success  considering  its commercial and  technical  feasibility;  that  the 
Company  is  able  to  use  or  sell  the  asset;  the  Company  has  sufficient  resources  and  intent  to  complete  the 
development; and its costs can be measured reliably.  Capitalised development costs are amortised on a straight-
line basis over the period of their expected benefit. 
Trade and other payables 
These  amounts  represent  liabilities  for goods  and  services provided  to  the  Company  prior  to  the end  of  the 
financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and 
are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 32 
 
 
 
 
 
 
  
 
 
  
  
  
  
 
 
 
 
 
 
 
  
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
Employee benefits 
Short-term employee benefits 
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected 
to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid 
when the liabilities are settled. 
Other long-term employee benefits 
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting 
date are measured at the present value of expected future payments to be made in respect of services provided 
by  employees  up  to  the  reporting  date  using  the  projected  unit  credit  method.  Consideration  is  given  to 
expected future wage and salary levels, experience of employee departures and periods of service. Expected 
future payments are discounted using market yields at the reporting date on corporate bonds with terms to 
maturity and currency that match, as closely as possible, the estimated future cash outflows. 
Share-based payments 
Equity-settled and cash-settled share-based compensation benefits are provided to employees. 
Equity-settled  transactions  are  awards  of  shares,  or  options  over  shares  that  are  provided  to  employees  in 
exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, 
where the amount of cash is determined by reference to the share price. 
The  cost  of  equity-settled  transactions  is  measured  at  fair  value  on  grant  date.  Fair  value  is  independently 
determined using either the Binomial or Black-Scholes option pricing model that takes into account the exercise 
price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility 
of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, 
together with non-vesting conditions that do not determine whether the Company receives the services that 
entitle the employees to receive payment. No account is taken of any other vesting conditions. 
The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over 
the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the 
award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting 
period.  The  amount  recognised  in  profit  or  loss  for  the  period  is  the  cumulative  amount  calculated  at  each 
reporting date less amounts already recognised in previous periods. 
The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying 
either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions 
on  which  the  award  was  granted.  The  cumulative  charge  to  profit  or  loss  until  settlement  of  the  liability  is 
calculated as follows: 
• 
• 
during the vesting period, the liability at each reporting date is the fair value of the award at that date 
multiplied by the expired portion of the vesting period. 
from the end of the vesting period until settlement of the award, the liability is the full fair value of the 
liability at the reporting date. 
All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the 
cash paid to settle the liability. 
Market  conditions  are  taken  into  consideration  in  determining  fair  value.  Therefore,  any  awards  subject  to 
market conditions are considered to vest irrespective of whether or not that market condition has been met, 
provided all other conditions are satisfied. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 33 
 
 
 
 
 
 
 
  
 
  
  
  
  
 
  
  
  
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been 
made.  An  additional  expense  is  recognised,  over  the  remaining  vesting  period,  for  any  modification  that 
increases the total fair value of the share-based compensation benefit as at the date of modification. 
If the non-vesting condition is within the control of the Company or employee, the failure to satisfy the condition 
is treated as a cancellation. If the condition is not within the control of the Company or employee and is not 
satisfied  during  the  vesting  period,  any  remaining  expense  for  the  award  is  recognised  over  the  remaining 
vesting period, unless the award is forfeited. 
If  equity-settled  awards  are  cancelled,  it  is  treated  as  if  it  has  vested  on  the  date  of  cancellation,  and  any 
remaining  expense  is  recognised  immediately.  If  a  new  replacement  award  is  substituted  for  the  cancelled 
award, the cancelled and new award is treated as if they were a modification. 
Lease liabilities 
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at 
the present value of the lease payments to be made over the term of the lease, discounted using the interest 
rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing 
rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments 
that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price 
of  a  purchase  option  when  the  exercise  of  the  option  is  reasonably  certain  to  occur,  and  any  anticipated 
termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in 
the period in which they are incurred. 
Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are 
remeasured if there is a change in the following: future lease payments arising from a change in an index or a 
rate  used;  residual  guarantee; lease  term; certainty  of  a  purchase  option  and  termination  penalties.  When  a 
lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss 
if the carrying amount of the right-of-use asset is fully written down. 
Finance costs 
Finance costs  attributable  to  qualifying  assets  are  capitalised  as  part  of  the  asset.  All  other finance  costs  are 
expensed in the period in which they are incurred. 
Borrowings 
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction 
costs. They are subsequently measured at amortised cost using the effective interest method. 
Fair value measurement 
When  an  asset  or  liability,  financial  or  non-financial,  is  measured  at  fair  value  for  recognition  or  disclosure 
purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability 
in  an  orderly  transaction  between  market  participants  at  the  measurement  date;  and  assumes  that  the 
transaction will take place either: in the principal market; or in the absence of a principal market, in the most 
advantageous market. 
Fair  value  is  measured  using  the  assumptions  that  market  participants  would  use  when  pricing  the  asset  or 
liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement 
is  based  on its  highest  and  best  use. Valuation  techniques that  are  appropriate  in  the  circumstances  and  for 
which sufficient data are available to measure fair value, are used, maximising the use of relevant observable 
inputs and minimising the use of unobservable inputs. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 34 
 
 
 
 
  
 
  
 
  
  
 
 
 
 
 
  
  
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
Assets and liabilities measured at fair value are classified into three levels using a fair value hierarchy that reflects 
the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting 
date and transfers between levels are determined based on a reassessment of the lowest level of input that is 
significant to the fair value measurement. 
For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise 
is either not available or when the valuation is deemed to be significant. External valuers are selected based on 
market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from 
one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the 
latest valuation and a comparison, where applicable, with external sources of data. 
Issued capital 
Ordinary shares are classified as equity. 
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, 
net of tax, from the proceeds. 
Dividends 
Dividends  are  recognised  when  declared  during  the  financial  year  and  no  longer  at  the  discretion  of  the 
Company. 
Goods and Services Tax ('GST') and other similar taxes 
Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is 
not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the 
asset or as part of the expense. 
Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of 
GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the 
statement of financial position. 
Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing 
activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. 
Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the 
tax authority. 
Associates 
Associates  are  entities  over  which  the  Company  has  significant  influence  but  not  control  or  joint  control. 
Investments in associates are accounted for using the equity method. Under the equity method, the share of 
the profits or losses of the associate is recognised in profit or loss and the share of the movements in equity is 
recognised in other comprehensive income. Investments in associates are carried in the statement of financial 
position at cost plus post acquisition changes in the Company’s share of net assets of the associate. Dividends 
received or receivable from associates reduce the carrying amount of the investment. 
When the Company's share of losses in an associate equals or exceeds its interest in the associate, including any 
unsecured  long-term  receivables,  the  Company  does  not  recognise  further  losses,  unless  it  has  incurred 
obligations or made payments on behalf of the associate. 
The Company discontinues the use of the equity method upon the loss of significant influence over the associate 
and  recognises  any  retained  investment  at  its  fair  value.  Any  difference  between  the  associate's  carrying 
amount, fair value of the retained investment and proceeds from disposal is recognised in profit or loss. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 35 
 
 
 
 
  
 
 
  
  
 
  
 
  
  
  
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) 
New Accounting Standards and Interpretations not yet mandatory or early adopted 
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet 
mandatory, have not been early adopted by the Company for the annual reporting period ended 30 June 2023. 
The  Company  has  not  yet  assessed  the  impact  of  these  new  or  amended  Accounting  Standards  and 
Interpretations. 
NOTE 2. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS 
The  preparation  of  the  financial  statements  requires  management  to  make  judgements,  estimates  and 
assumptions that affect the reported amounts in the financial statements. Management continually evaluates 
its  judgements  and  estimates  in  relation  to  assets,  liabilities,  contingent  liabilities,  revenue  and  expenses. 
Management bases its judgements, estimates and assumptions on historical experience and on other various 
factors,  including  expectations  of  future  events,  management  believes  to  be  reasonable  under  the 
circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. 
The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the 
carrying  amounts  of  assets  and  liabilities  (refer  to  the  respective  notes)  within  the  next  financial  year  are 
discussed below. 
Share-based payment transactions 
The Company measures the cost of equity-settled transactions with employees by reference to the fair value of 
the equity instruments at the date at which they are granted. Management has applied a probability estimate 
to the vesting conditions being met, since the Company was unable to reliably measure the fair value of the 
services received. The accounting estimates and assumptions relating to equity-settled share-based payments 
would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period 
but may impact profit or loss and equity.  
NOTE 3. OPERATING SEGMENTS 
Primary Reporting Format – Business Segments 
The Company has one geographical location which is Australia. The Company’s sole operations are research and 
development, and promotion of the Company’s nanocellulose technology from that location. 
Identification of reportable operating segments 
The operating segment identified is based on the internal reports that are reviewed and used by the Directors 
(who  are  identified  as  the  Chief  Operating  Decision  Makers  ('CODM'))  in  assessing  performance  and  in 
determining  the  allocation  of  resources. There is  no  aggregation  of  operating  segments.  The  CODM reviews 
EBITDA  (Earnings  Before  Interest,  Tax,  Depreciation  and  Amortisation).  The  accounting  policies  adopted  for 
internal reporting to the CODM are consistent with those adopted in the financial statements. The information 
reported to the CODM is on at least a quarterly basis. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 36 
 
 
 
 
 
 
  
  
  
 
 
 
  
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 4. INCOME TAX EXPENSE  
Reconciliation of income tax expense and tax at the statutory rate 
Loss before income tax expense from continuing operations 
      (1,345,656) 
      (1,566,504) 
30 June 2023 ($) 
30 June 2022 ($) 
Tax benefit at the statutory tax rate of 30% (2022: 30%) 
       403,697 
       469,951 
Tax effect amounts which are not deductible/(taxable) in 
calculating taxable income: 
Non-assessable income 
Other non-deductible expenses 
- 
- 
        (21,550) 
        (22,072) 
382,147 
447,879 
Future tax benefit not recognised 
      (382,147) 
      (447,879) 
Income tax expense 
- 
- 
Unrecognised deferred tax balances 
The  Company  does  not  currently  recognise  any  deferred  tax  asset  arising  from  its  tax  losses.  The  Directors 
estimate that the potential deferred tax assets at 30% not brought to account attributable to tax losses carried 
forward at reporting date is approximately $1,842,531 (2022: $1,622,968).  
The losses have not been brought to account because the Directors do not believe it is appropriate to regard 
realisation of those deferred tax assets as being probable. The benefit of these deferred tax assets will only be 
obtained if: 
(1) 
(2) 
(3) 
the Company derives future assessable income of a nature and of an amount sufficient to enable the 
benefit from the deductions for the temporary differences to be realised; 
the Company continues to comply with the conditions for deductibility imposed by tax legislation; and 
no changes in tax legislation adversely affect the Company in realising the benefit from the 
deductions for the temporary differences. 
NOTE 5. CASH AND CASH EQUIVALENTS 
Cash at bank 
Term deposit [1] 
30 June 2023 ($) 
30 June 2022 ($) 
         528,248 
         366,252 
20,000 
1,220,000 
[1] Term deposit amount includes $20,000 used as security for credit cards. 
548,248 
1,586,252 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 6. RIGHT OF USE ASSET 
Right of use asset 
Accumulated depreciation 
Right of use asset 
Opening balance 
Additions 
Closing balance 
Accumulated depreciation 
Opening balance 
Depreciation expense 
30 June 2023 ($) 
30 June 2022 ($) 
153,190 
153,190 
        (142,169) 
        (115,719) 
11,021 
37,471 
153,190 
- 
153,190 
100,289 
52,901 
153,190 
        (115,719) 
        (89,842) 
(26,450) 
(142,169) 
11,021 
(25,877) 
(115,719) 
37,471 
NOTE 7. INVESTMENT IN ASSOCIATE 
Interests in associate are accounted for using the equity method of accounting. 
Name 
Principal place of business / 
Country of incorporation 
30 June 2023 (%) 
30 June 2022 (%) 
CelluAir Pty Ltd 
Australia 
18.95 
20 
Ownership Interest  
Interests  in  associates  are  accounted  for  using  the  equity  method  of  accounting.  During  the  period,  the 
Company’s interest in CelluAir Pty Ltd fell below 20% and the investment is no longer accounted for using the 
equity method of accounting.  
The Directors have assessed the carry value of the investment in CelluAir Pty Ltd as at 30 June 2023 and have 
written  down  the  book  value  of  the  investment  to  zero,  and  accordingly  the  amount  of  $160,199  has  been 
impaired during the financial year. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 38 
 
 
 
 
 
 
 
 
 
 
 
 
         
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 8.  PLANT AND EQUIPMENT 
Plant and equipment – at cost 
Accumulated depreciation 
Leasehold improvements – at cost 
Accumulated depreciation 
Reconciliations 
30 June 2023 ($) 
30 June 2022 ($) 
86,600 
142,632 
      (74,380) 
      (92,800) 
       12,220 
       49,832 
       58,251 
(47,999) 
       10,252 
      22,472 
       58,251 
(44,594) 
       13,657 
       63,489 
Reconciliations of the written down values at the beginning and end of the current and previous financial year 
are set out below: 
Balance at 30 June 2022 
Additions 
Disposals 
Depreciation expense 
Plant and 
equipment ($) 
Leasehold 
improvements ($) 
Total ($) 
49,832 
- 
(30,698) 
(6,914) 
        13,657 
                 - 
       (3,405) 
63,489 
         - 
(30,698) 
(10,319) 
Balance at 30 June 2023 
12,220 
        10,252 
22,472 
NOTE 9. TRADE AND OTHER PAYABLES 
Trade payables 
Other payables 
Refer to Note 23 for further information on financial instruments. 
30 June 2023 ($) 
30 June 2022 ($) 
43,024 
49,758 
37,163 
51,014 
     92,782 
     88,177 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 10. PROVISIONS 
Provision for annual leave 
30 June 2023 ($) 
30 June 2022 ($) 
      77,305 
      55,239 
The  current  provision  for  employee  benefits  includes  all  unconditional  entitlements  where  employees  have 
completed the required period of service and also those where employees are entitled to pro-rata payments in 
certain  circumstances.  The  entire  amount  is  presented  as  current  since  the  Company  does  not  have  an 
unconditional right to defer settlement. 
NOTE 11. LEASE LIABILITY 
Lease liability - current 
30 June 2023 ($) 
30 June 2022 ($) 
11,519 
38,093 
The lease liability relates to the lease of  premises with an annual rental of $27,600 and an expiry date of 25 
November 2023, hence the remaining liability has been classified as current. 
NOTE 12. EQUITY - ISSUED CAPITAL 
Ordinary shares - fully paid 
148,886,368 
148,886,368 
8,975,496 
          8,975,496 
2023 (shares) 
2022 (shares) 
2023($) 
2022 ($) 
Movements in ordinary share capital 
Balance as at 30 June 2022 
Balance as at 30 June 2023 
    Date 
 Shares    
     Issue price 
$ 
148,886,368 
    8,975,496 
- 
- 
148,886,368 
    8,975,496 
Balance as at 30 June 2021 
148,686,368 
    8,955,496 
    Date 
 Shares    
     Issue price 
$ 
Conversion of options 
   16 November 2021 
200,000 
$0.100 
20,000 
Balance as at 30 June 2022 
148,886,368 
    8,975,496 
Ordinary shares 
Ordinary  shares  entitle  the  holder  to  participate  in  dividends  and  the  proceeds  on  the  winding  up  of  the 
Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares 
have no par value and the Company does not have a limited amount of authorised capital. 
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a 
poll each share shall have one vote. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 13. EQUITY – RESERVES 
Options reserve (a) 
Performance rights reserve (b) 
(a)  Movements in options reserve 
30 June 2023 ($) 
30 June 2022 ($) 
1,101,666 
21,729 
1,123,395 
1,054,426 
- 
1,054,426 
Balance as at 30 June 2021 
   No. of Options 
$ 
          4,700,000 
                 587,576 
5 July 2021                  Issue of NC6OA options to placement participants  
& lead manager 
       22,268,635 
                 329,250 
15 September 2021   Issue of I Class options to employee 
         1,000,000 
                   52,400 
16 November 2021   Exercise of F Class options 
           (200,000) 
                              - 
30 November 2021   Expiry of F Class options 
       (2,200,000) 
                              - 
7 December 2021      Issue of J Class options to Directors 
         1,000,000 
                   85,200 
Balance as at 30 June 2022 
       26,568,635 
               1,054,426 
13 December 2022   Issue of K Class options to Director 
          1,000,000 
                    34,640 
20 January 2023        Issue of L Class options to consultant 
             500,000 
                    12,600 
31 May 2023              Expiry of NC6OPT1 options 
           (800,000) 
                              - 
Balance as at 30 June 2023 
       27,268,635 
               1,101,666 
For the options granted during the current financial year, the valuation model inputs used to determine the 
fair value at the grant date, are as follows: 
The expense of $34,640 for options issued to Directors was calculated using the Hoadley ESO2 valuation model 
using the following inputs: 
Number of options in series 
Grant date 
Expiry date 
Share price at grant date 
Exercise price 
Expected volatility 
Dividend yield 
Risk-free interest rate 
Fair value at grant date 
Unlisted options 
NC6OPT 7  
1,000,000 
25 Nov 2022 
13 Dec 2024 
$0.075 
$0.10 
100% 
nil 
3.19% 
$0.0346 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 13. EQUITY – RESERVES (CONTINUED) 
The expense of $12,600 for options issued to consultant was calculated using the Hoadley ESO2 valuation model 
using the following inputs: 
Number of options in series 
Grant date 
Expiry date 
Share price at grant date 
Exercise price 
Expected volatility 
Dividend yield 
Risk-free interest rate 
Fair value at grant date 
Unlisted options 
NC6OPT 8  
500,000 
20 Jan 2023 
20 Jan 2026 
$0.06 
$0.10 
95% 
nil 
2.99% 
$0.0252 
The options on issue as at 30 June 2023 are as follows: 
   Grant date 
Class of option 
No. of Options 
Exercise price 
                 Expiry date 
   4 December 2020 
   20 April 2021 
   5 July 2021 
   14 September 2021 
   26 November 2021 
   13 December 2022 
   20 January 2023 
   Total 
Class G 
Class H 
NC6OA 
Class I 
Class J 
Class K 
Class L 
           500,000 
         $0.08 
31 October 2023 
        1,000,000 
         $0.10 
20 April 2024 
22,268,635 
1,000,000 
1,000,000 
1,000,000 
500,000 
        27,268,635 
$0.15 
$0.15 
5 July 2024 
15 September 2024 
$0.147 
7 December 2024 
$0.10 
$0.10 
13 December 2024 
20 January 2026 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 13. EQUITY – RESERVES (CONTINUED) 
(b)  Movements in performance rights reserve 
Balance as at 30 June 2021 
D Class Performance rights lapsed 
Balance as at 30 June 2022 
E Class Performance Rights issued to director - expense recognised for the year end 30 June 
2023 
Balance as at 30 June 2023 
No. of 
Performance 
Rights 
$ 
2,000,000 
65,835 
   (2,000,000) 
(65,835) 
- 
- 
   1,000,000 
21,729 
1,000,000 
21,729 
1,000,000 performance rights were issued to director, Wayne Best. An expense of $21,729 was recognised in 
the financial year ended 30 June 2023.  
Number of performance rights 
Grant date 
Vesting date 
Share price at grant date 
Probability of vesting 
E Class Performance 
Rights  
1,000,000 
25 Nov 2022 
13 Dec 2024 
$0.075 
100% 
A summary of share-based payments recognised as expenses/share issued costs for the year are as follows:  
Share-based payment – employees/KMP 
30 June 2023 ($) 
30 June 2022 ($) 
Options issued to employee 
Options issued to directors 
Performance rights issued to directors 
Performance rights to director lapsed 
Share-based payment – supplier/consultant 
Options issued to lead manager – recognised in equity 
Options issued to consultant – recognised in profit or loss 
34,640 
21,729 
- 
56,369 
- 
12,600 
12,600 
52,400 
85,200 
- 
(65,835) 
71,765 
329,250 
- 
  329,250 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 14. EQUITY – ACCUMULATED LOSSES 
Accumulated losses at the beginning of the financial year 
            (8,301,603) 
Loss after income tax expense for the year 
(1,345,656) 
(6,735,099) 
(1,566,504) 
Accumulated losses at the end of the financial year 
  (9,647,259) 
  (8,301,603) 
30 June 2023 ($) 
30 June 2022 ($) 
NOTE 15. KEY MANAGEMENT PERSONNEL COMPENSATION 
Key management personnel remuneration has been included in the Remuneration Report section of the 
Directors’ Report. 
Short-term employee benefits 
Post-employment benefits 
Annual leave payments  
Share-based payments - shares 
Share-based payments - options 
Share-based payments - performance rights 
30 June 2023 ($) 
30 June 2022 ($) 
330,000 
23,625 
15,970 
- 
34,640 
21,729 
425,964 
330,000 
22,669 
18,213 
- 
85,200 
(65,835) 
390,247 
NOTE 16. REMUNERATION OF AUDITORS 
During the financial year the following fees were paid or payable for services provided by RSM Australia 
Partners, the auditor of the Company: 
Audit services – RSM Australia Partners 
Auditor review of the financial statements 
Other services – RSM Australia Pty Ltd 
Preparation of income tax return 
30 June 2023 ($) 
30 June 2022 ($) 
36,950       
33,500       
7,000 
43,950 
6,500 
40,000 
NOTE 17. COMMITMENTS  
The Company has no commitments not recognised as liabilities as at 30 June 2023 (2022: $nil). 
NOTE 18. CONTINGENT ASSETS  
The Company has no contingent assets as at 30 June 2023 (2022: $nil). 
NOTE 19. CONTINGENT LIABILITIES 
The Company has no contingent liabilities as at 30 June 2023 (2022: $nil).  
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 20. EVENTS AFTER THE REPORTING PERIOD 
No matter  or  circumstance has  arisen  since  30  June  2023 that  has  significantly affected,  or may  significantly 
affect  the  Company's  operations,  the results  of  those  operations,  or  the  Company's  state  of  affairs in future 
financial years. 
NOTE 21. RELATED PARTY TRANSACTIONS 
Disclosures relating to key management personnel are set out in Note 15 and the Remuneration Report included 
in the Directors’ Report. 
Transactions with key management personnel and their related parties 
Payments to Azalea Accounting Services Pty Ltd (director related entity of Winton Willesee) of Nil (2022: $22,00) 
for bookkeeping and financial reporting services fees. 
Payments to Azalea Corporate Services Pty Ltd (director related entity of Winton Willesee) of $82,451 (2022: 
$60,451)  for  bookkeeping  and  financial  reporting  services  fees,  corporate  services  fees  including  company 
secretarial services, and front and registered office services.  
Receivable from and payable to key management personnel and their related parties are as follows: 
The following balances are outstanding at the reporting date in relation to transactions with key management 
personnel and their related parties: 
Payable to Azalea Accounting Services Pty Ltd (director related entity of Winton Willesee) 
2023 
- 
Payable to Azalea Corporate Services Pty Ltd (director related entity of Winton Willesee) 
10,412 
2022 
2,000 
5,496 
Transactions between related parties are on normal commercial terms and conditions no more favourable than 
those available to other parties unless otherwise stated.  
There  were  no  further  transactions  with  Directors  or  other  Key  Management  Personnel,  including  their 
personally related parties, not disclosed in Note 15 or the above. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 22. RECONCILIATION OF LOSS AFTER INCOME TAX TO NET CASH USED IN OPERATING ACTIVITIES 
Loss after income tax expense for the year 
Adjustments for: 
Depreciation of plant and equipment 
Depreciation of right-of-use-asset  
Net loss on disposal of property, plant and equipment 
Impairment on investment 
Share based payments 
Change in operating assets and liabilities: 
Trade and other receivables 
Prepayments 
Provisions 
Trade and other payables 
Net cash used in operating activities 
30 June 2023 ($)  30 June 2022 ($) 
(1,345,656) 
(1,566,504) 
10,319 
26,450 
30,698 
160,199 
68,969 
(46) 
10,966 
22,066 
4,605 
39,128 
25,876 
- 
16,356 
71,765 
12,612 
15,749 
30,451 
(27,739) 
(1,011,430) 
(1,382,306) 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 23. FINANCIAL INSTRUMENTS 
The Company’s activities are being funded by equity and are not exposed to significant financial risks.  There 
are no speculative or financial derivative instruments.  The Company holds the following financial instruments: 
Financial assets 
Cash and cash equivalents 
Trade and other receivables 
Financial liabilities 
Trade and other payables 
Lease liability  
30 June 2023 ($) 
30 June 2022 ($) 
548,248 
20,452 
568,700 
1,586,252 
20,406 
1,606,658 
             92,782 
             88,177 
               11,519 
               38,093 
             104,301 
             126,270 
The  Company’s  principal  financial  instruments  comprise  of  cash.  The  main  purpose  of  these  financial 
instruments is to fund the Company’s operations. 
It  is,  and  has  been  throughout  the  period  under  review,  the  Company’s  policy  that  no  trading  in  financial 
instruments shall be undertaken.  The main risks arising from the Company’s financial operations are credit risk, 
capital risk and liquidity risk.  The Directors’ review and agree policies for managing each of these risks and they 
are summarised below: 
(a) 
Credit risk 
Management does not actively manage credit risk as the Company has no significant exposure to credit risk from 
external parties at year end as there are no trade receivables. 
(b) 
Capital risk 
The Company’s objectives when managing capital are to safeguard its ability to continue as a going concern, so 
that it can continue to provide returns for shareholders and benefits for other stakeholders and to maintain an 
optimal capital structure to reduce the cost of capital.  In order to maintain or adjust the capital structure, the 
Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new 
shares or sell assets to reduce debt. 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTES TO THE FINANCIAL STATEMENTS 
NOTE 23. FINANCIAL INSTRUMENTS (CONTINUED) 
(c) 
Liquidity risk 
Maturity profile of financial instruments   
Prudent liquidity risk management implies maintaining sufficient cash balances and access to equity funding.  
The  Company’s  exposure  to  the risk  of  changes in market interest  rates  relates  primarily  to cash  assets  and 
floating  interest  rates.  The  Company  does  not  have  significant  interest-bearing  assets  and  is  not  materially 
exposed to changes in market interest rates. 
The Company does not have financial instruments with maturity exceeding 12 months (2022: $nil).  
 Sensitivity analysis – interest rates 
 The sensitivity effect of possible interest rate movements has not been disclosed as they are not material.  
(d) 
Net fair value of financial assets and liabilities 
 Unless otherwise stated, the carrying amount of financial instruments reflect their fair value. 
NOTE 24. LOSS PER SHARE 
Basic loss per share (cents) 
Diluted loss per share (cents) 
30 June 2023 ($) 
30 June 2022 ($) 
0.90 
0.90 
1.05 
1.05 
30 June 2023($) 
30 June 2022 ($) 
Net loss used in the calculation of basic and diluted loss per share 
Weighted average number of ordinary shares outstanding during the year 
used in the calculation of basic loss per share 
Weighted average number of ordinary shares outstanding during the year 
used in the calculation of diluted loss per share 
          (1,345,656) 
          (1,566,504) 
148,886,368 
148,810,204 
148,886,368 
148,810,204 
As the Company is in a loss position, the diluted loss per share calculation excludes the dilutive effect of the 
performance rights and options issued and not yet converted to ordinary shares. 
NOTE 25. DIVIDENDS  
There were no dividends declared or paid during the financial year (2022: Nil). 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DIRECTOR’S DECLARATION   NANOLLOSE LIMITED ANNUAL REPORT 2023 PAGE 49 In the opinion of the Directors of Nanollose Limited: (a) the attached Financial Statements and Notes are in accordance with the Corporations Act 2001, including: (i) giving a true and fair view of the Company’s financial position as at 30 June 2023 and of its performance, for the financial period ended on that date; and (ii) complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and Corporations Regulations 2001; and other mandatory professional reporting requirements.  (b) the Financial Report also complies with International Financial Reporting Standards as issued by the International Accounting Standards Board as disclosed in Note 1 to the financial statements; and (c) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable. The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 by the Financial Officer and Chief Executive Officer for the financial period ended 30 June 2023.  Signed in accordance with a resolution of the Directors.   Winton Willesee Non-Executive Director Dated at Perth, Western Australia 28 August 2023 Level 32 Exchange Tower, 2 The Esplanade Perth WA 6000 
GPO Box R1253 Perth WA 6844 
RSM Australia Partners 
T +61 (0) 8 9261 9100 
F +61 (0) 8 9261 9111 
www.rsm.com.au 
INDEPENDENT AUDITOR’S REPORT 
TO THE MEMBERS OF  
NANOLLOSE LIMITED 
Opinion 
We  have  audited  the  financial  report  of  Nanollose  Limited  (the  Company),  which  comprises  the  statement  of 
financial  position  as  at  30  June  2023,  the  statement  of  profit  or  loss  and  other  comprehensive  income,  the 
statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial 
statements, including a summary of significant accounting policies, and the directors' declaration. 
In our opinion, the accompanying financial report of the Company is in accordance with the Corporations Act 2001, 
including:  
(i) 
Giving  a  true  and  fair  view  of  the  Company's  financial  position  as  at  30  June  2023  and  of  its  financial 
performance for the year then ended; and 
(ii) 
Complying with Australian Accounting Standards and the Corporations Regulations 2001. 
Basis for Opinion 
We  conducted  our  audit  in  accordance  with  Australian  Auditing  Standards.  Our  responsibilities  under  those 
standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of 
our report. We are independent of the Company in accordance with the auditor independence requirements of 
the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards 
Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the 
financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.  
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to 
the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's 
report. 
We  believe  that  the  audit  evidence  we  have  obtained  is  sufficient  and  appropriate  to  provide  a  basis  for  our 
opinion. 
THE POWER OF BEING UNDERSTOOD 
AUDIT | TAX | CONSULTING 
RSM Australia Partners is a member of the RSM network and trades as RSM.  RSM is the trading name used by the members of the RSM network.  Each member of the RSM network is an independent 
accounting and consulting firm which practices in its own right.  The RSM network is not itself a separate legal entity in any jurisdiction. 
RSM Australia Partners ABN 36 965 185 036 
Liability limited by a scheme approved under Professional Standards Legislation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material Uncertainty Related to Going Concern 
We draw attention to Note 1, which indicates that the Company incurred a loss of $1,345,656 and had net cash 
outflows  from  operating  activities  of  $1,011,430  for  the  financial  year  ended  30  June  2023.  These  events  or 
conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast 
significant doubt on the Company’s ability to continue as a going concern. Our opinion is not modified in respect 
of this matter.  
Key Audit Matters 
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of 
the financial report of the current period. These matters were addressed in the context of our audit of the financial 
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. 
In  addition  to  the  matter  described  in  the  Material  Uncertainty  Related  to  Going  Concern  section,  we  have 
determined the matters described below to be the key audit matters to be communicated in our report.  
Key Audit Matter 
Share-based payments 
Refer to Note 13 to the financial statements 
How our audit addressed this matter 
During  the  year,  the  Company  issued  options  and 
performance rights to a director and a consultant.  
Our audit procedures included: 
•  Reviewing the terms and conditions of the options 
and performance rights issued;  
We determined this to be a key audit matter due to the 
significant  judgements  involved  in  assessing  the  fair 
value  of  the  options  and  performance  rights  issued 
during the year.  
•  Obtaining  the  valuation  models  prepared  by 
management and assessing whether the models 
were  appropriate  for  valuing  the  options  and 
performance rights granted during the year; 
of 
key 
assumptions  used  by  management  to  value  the 
options and performance rights;  
•  Challenging 
reasonableness 
the 
•  Recalculating 
the  value  of 
payment  expense 
statement  of  profit  or 
comprehensive income; and  
to  be  recognised 
the  share-based 
the 
loss  and  other 
in 
•  Assessing the adequacy of the disclosures in the 
financial  statements  to  ensure  compliance  with 
Australian Accounting Standards. 
Other Information  
The directors are responsible for the other information. The other information comprises the information included 
in the Company's annual report for the year ended 30 June 2023 but does not include the financial report and the 
auditor's report thereon.  
Our opinion on the financial report does not cover the other information and accordingly we do not express any 
form of assurance conclusion thereon.  
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing 
so, consider whether the other information is materially inconsistent with the financial report or our knowledge 
obtained in the audit or otherwise appears to be materially misstated.  
If,  based  on  the  work  we  have  performed,  we  conclude  that  there  is  a  material  misstatement  of  this  other 
information, we are required to report that fact. We have nothing to report in this regard.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Responsibilities of the Directors for the Financial Report 
The directors of the Company are responsible for the preparation of the financial report that gives a true and fair 
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal 
control as the directors determine is necessary to enable the preparation of the financial report that gives a true 
and fair view and is free from material misstatement, whether due to fraud or error.  
In preparing the financial report, the directors are responsible for assessing the ability of the Company to continue 
as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis 
of  accounting  unless  the  directors  either  intend  to  liquidate  the  Company  or  to  cease  operations,  or  have  no 
realistic alternative but to do so.  
Auditor's Responsibilities for the Audit of the Financial Report 
Our  objectives  are  to  obtain  reasonable  assurance  about  whether  the  financial  report  as  a  whole  is  free  from 
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. 
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance 
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements 
can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably 
be expected to influence the economic decisions of users taken on the basis of this financial report.  
A  further  description  of  our  responsibilities  for  the  audit  of  the  financial  report  is  located  at  the  Auditing  and 
Assurance  Standards  Board  website  at:  http://www.auasb.gov.au/auditors_responsibilities/ar2.pdf.  This 
description forms part of our auditor's report.  
Report on the Remuneration Report 
Opinion on the Remuneration Report 
We have audited the Remuneration Report included within the directors’ report for the year ended 30 June 2023.  
In our opinion, the Remuneration Report of Nanollose Limited, for the year ended 30 June 2023, complies with 
section 300A of the Corporations Act 2001.  
Responsibilities 
The directors of the Company are responsible for the preparation and presentation of the Remuneration Report 
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the 
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.  
RSM AUSTRALIA PARTNERS 
Perth, WA 
Dated: 28 August 2023 
Alasdair Whyte 
Partner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASX ADDITIONAL INFORMATION 
The shareholder information set out below was applicable as at 1 August 2023. 
1.  Quotation  
Listed securities in Nanollose Limited are quoted on the Australian Securities Exchange under ASX code NC6 
(Fully Paid Ordinary Shares) and NC6OA (Listed Options) and are not quoted on any other exchange. 
2.  Voting Rights 
The voting rights attached to the Fully Paid Ordinary Shares (“Shares”) of the Company are: 
(a)  at a meeting of members or classes of members each member entitled to vote may vote in person or by 
proxy or by attorney; and 
(b)  every member present in person, or by proxy or attorney: 
(i)  on a show of hands, has one vote; and  
(ii)  on a poll, has one vote for each Share held. 
There are no voting rights attached to any Options or Performance Rights on issue. 
3.  Distribution of Shareholders 
i) 
Fully Paid Ordinary Shares 
Shares Range 
Holders 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
33 
177 
255 
692 
182 
1,339 
Units 
4,813 
693,907 
2,069,499 
26,183,858 
119,934,291 
148,886,368 
% 
- 
0.47% 
1.39% 
17.59% 
80.55% 
100.00% 
On 1 August 2023, there were 363 holders of unmarketable parcels of less than 9,091 Shares (based on 
the closing Share price of $0.055).  
ii)  Listed Options exercisable at $0.15 on or before 5 July 2024 
Shares Range 
Holders 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
1 
5 
3 
66 
22 
97 
Units 
5 
21,421 
28,809 
3,198,633 
19,019,767 
22,268,635 
% 
- 
0.10% 
0.13% 
14.36% 
85.41% 
100.00% 
NANOLLOSE LIMITED ANNUAL REPORT 2023 
PAGE 53 
 
 
 
 
 
 
 
 
ASX ADDITIONAL INFORMATION 
iii)  Class G Options exercisable at $0.08 on or before 31 October 2023 
Shares Range 
Holders 
Units 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
1Held by Heidi Beatty 
- 
- 
- 
- 
1 
1 
- 
- 
- 
- 
500,0001 
500,000 
iv)  Class H Options exercisable at $0.10 on or before 20 April 2024 
Shares Range 
Holders 
Units 
1 – 1,000 
1,001 – 5,000 
5,001 – 10,000 
10,001 – 100,000 
100,001 and above 
Total 
- 
- 
- 
- 
1 
1 
- 
- 
- 
- 
1,000,0001 
1,000,000 
1Held by Cheena Corporate Pty Ltd 
Continue reading text version or see original annual report in PDF format above